TY - JOUR T1 - Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy JF - Gut JO - Gut SP - 1922 LP - 1924 DO - 10.1136/gutjnl-2021-326196 VL - 71 IS - 9 AU - Zahra Jama Shire AU - Frederic Reicherz AU - Sally Lawrence AU - Harjeev Sudan AU - Liam Golding AU - Abdelilah Majdoubi AU - Paul N Levett AU - Pascal M Lavoie AU - Kevan Jacobson Y1 - 2022/09/01 UR - http://gut.bmj.com/content/71/9/1922.abstract N2 - We read with interest the recent findings by Kennedy et al, which concluded that infliximab (IFX) impairs antibody responses to a single dose of the mRNA-BNT162b2 SARS-CoV-2 vaccine in adult patients with IBD.1 2 Interestingly, another study showed that antibodies against SARS-CoV-2 diminish over time following infection in adult patients with IBD.3 In general, more robust antibody responses have been observed in adolescents compared with adults in the BNT162b2 vaccine trial.4 However, the true impact of immunosuppressant therapies on SARS-CoV-2 vaccine efficacy in paediatric IBD (PIBD) patients is unknown as they were excluded from the trials. Therefore, analysing vaccine responses directly in these patients is necessary to determine the best strategy.5 6 We undertook a study to evaluate immunogenicity of mRNA-based SARS-CoV-2 vaccines in PIBD patients treated with anti-TNF therapies. Given the urgent need for data, we herein present preliminary findings. The study prospectively enrolled PIBD patients 12–17 years, treated with anti-TNF agents either alone or in combination with an immunomodulator, who received the BNT162b2 vaccine. Serum antibody levels for (spike protein, receptor-binding domain (RBD) and nucleocapsid protein) were measured at baseline, 28 days and 3 months after the first vaccine dose. Antibody responses were assessed using the V-PLEX SARS-CoV-2 Panel 2 (IgG) assay (Meso Scale … ER -